Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s FDA Progress and Market Potential

Aquestive Therapeutics (AQST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.

Ram Selvaraju has given his Buy rating due to a combination of factors surrounding Aquestive Therapeutics’ Anaphylm product. The FDA’s acceptance of the New Drug Application for Anaphylm, a non-device-based epinephrine product, is a significant milestone. This product has shown clinical results comparable to existing autoinjectors for treating severe allergic reactions, and the potential FDA decision is expected by early 2026. The possibility of an advisory committee meeting provides an opportunity for Aquestive to emphasize Anaphylm’s benefits, which are anticipated to be less complex than those of nasal spray-based alternatives.
Furthermore, Aquestive is actively preparing for the potential U.S. launch of Anaphylm in the first quarter of 2026, contingent on FDA approval. The company is focusing on optimizing market access and raising awareness through its medical affairs strategy. The Anaphylm NDA benefits from a 10-month review period, and the product is expected to generate significant sales, with projections exceeding $226 million by 2035. The planned sales force expansion further supports the commercial potential of Anaphylm, reinforcing the Buy rating with a 12-month price target of $10.

In another report released yesterday, Lake Street also maintained a Buy rating on the stock with a $8.00 price target.